|
|
Shi L, Sun X, Wang X, Zhao H. Exploration of key targets and mechanisms in radiotherapy-induced gastrointestinal mucositis: A systematic literature review. Int J Radiat Res 2025; 23 (3) :771-782 URL: http://ijrr.com/article-1-6679-en.html
Department of Gastroenterology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, Shandong, 266042, China , zhaohong1968qd@163.com
Abstract: (166 Views)
This review article explores the key targets and mechanisms of radiotherapy (RT)-induced gastrointestinal mucositis (RIGIM) development and progression. RIGIM is a frequent and potentially disabling side effect of radiation therapy, impacting the mucosal lining of the gastrointestinal tract. The pathophysiology of RIGIM is complex, involving oxidative stress, inflammatory pathways, DNA damage, changes in the gut microbiota, and disruption of the mucosal barrier’s integrity. The clinical presentation of RIGIM varies, ranging from mild inflammation to severe ulceration, significantly impacting patients’ quality of life, nutrition, and treatment adherence. This article discusses the risk factors, symptoms, and clinical manifestations of RIGIM, as well as current and potential therapeutic strategies. These strategies include pharmacological interventions, microbiome modulation, and supportive care, aimed at preventing, mitigating, or treating RIGIM and ultimately improving the lives of cancer patients undergoing RT.
References
1. Minniti G, Goldsmith C, Brada M (2012) Radiotherapy. Handb Clin Neurol, 104: 215-228. [ DOI:10.1016/B978-0-444-52138-5.00016-5] 2. Afifi ANAM, Powerski M, Jechorek D, et al. (2020) Radiation-induced damage in the upper gastrointestinal tract: clinical presentation, diagnostic tests and treatment options. Best Pract Res Clin Gastroenterol, 48-49: 101711. [ DOI:10.1016/j.bpg.2020.101711] 3. Khorashadizadeh S, Abbasifar S, Yousefi M, et al. (2024) The Role of microbiome and probiotics in chemo-radiotherapy-induced diarrhea: A narrative review of the current evidence. Cancer Rep, 7: e70029. [ DOI:10.1002/cnr2.70029] 4. Montovano M, Zhang M, Oh P, et al. (2021) Incidence and dosimetric predictors of radiation-induced gastric bleeding after chemoradiation for esophageal and gastroesophageal junction cancer. Adv Radiat Oncol, 6(3): 100648. [ DOI:10.1016/j.adro.2021.100648] 5. Tageja N, Groninger H (2014) Chemotherapy-induced nausea and vomiting (2016) Postgrad Med J, 92(1083):34-40 [ DOI:10.1136/postgradmedj-2014-132969] 6. Bowen JM, Gibson RJ, Coller JK, et al. (2019) Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines. Support Care Cancer, 27(10): 4011-4022. [ DOI:10.1007/s00520-019-04892-0] 7. Rao D, Behzadi F, Le RT, et al. (2021) Radiation induced mucositis: what the radiologist needs to know. Curr Probl Diagn Radiol, 50(6): 899-904. [ DOI:10.1067/j.cpradiol.2020.10.006] 8. Fuccio L, Guido A, Andreyev HJN (2012) Management of intestinal complications in patients with pelvic radiation disease. Clinical Gastroenterology and Hepatology, 10(12): 1326-1334.e4. [ DOI:10.1016/j.cgh.2012.07.017] 9. Dashnamoorthy S, Jeyasingh E, Ahmed I (2024) Comparison of normal tissue integral dose with monitor units from 3DCRT, IMRT, and Rapid Arc treatment planning methods for head and neck, pelvic and thoracic cancer sites. International Journal of Radiation Research, 22(4): 1019-1025. [ DOI:10.61186/ijrr.22.4.1019] 10. Miao B, Ruan G, Meng F, et al. (2025) The effects of radiofrequency ablation on lymphocytes, subsets and cytokines in patients with thyroid cancer: A meta-analysis. International Journal of Radiation Research, 23(1): 1-12. [ DOI:10.61186/ijrr.23.1.1] 11. Lu Q, Liang Y, Tian S, et al. (2023) Radiation-induced intestinal injury: injury mechanism and potential treatment strategies. Toxics, 11(12): 1011. [ DOI:10.3390/toxics11121011] 12. Jalili-Firoozinezhad S, Prantil-Baun R, Jiang A, et al. (2018) Modelling radiation injury-induced cell death and countermeasure drug responses in a human Gut-on-a-Chip. Cell Death & Disease, 9(2): 1-14. [ DOI:10.1038/s41419-018-0304-8] 13. Brizel D (2008) NCCN Task Force Report: Prevention and management of mucositis in cancer care. Journal of the National Comprehensive Cancer Network, 6 (Suppl 1): S1-21. [ DOI:10.6004/jnccn.2008.2001] 14. Elad S, Cheng KKF, Lalla RV, et al. (2020) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 126(19): 4423-4431. [ DOI:10.1002/cncr.33100] 15. Anderson CM, Lee CM, Kelley JR, et al. (2022) ROMAN: Phase 3 trial of avasopasem manganese (GC4419) for severe oral mucositis (SOM) in patients receiving chemoradiotherapy (CRT) for locally advanced, nonmetastatic head and neck cancer (LAHNC). Journal of Clinical Oncology, 40(16): 6005-6005. [ DOI:10.1200/JCO.2022.40.16_suppl.6005] 16. Wang K and Tepper JE (2021) Radiation therapy-associated toxicity: Etiology, management, and prevention. CA Cancer J Clin, 71(5): 437-454. [ DOI:10.3322/caac.21689] 17. Shadad AK, Sullivan FJ, Martin JD, et al. (2013) Gastrointestinal radiation injury: Symptoms, risk factors and mechanisms. World Journal of Gastroenterology: WJG, 19(2): 185-98. [ DOI:10.3748/wjg.v19.i2.185] 18. Zhou Y, Li K, Adelson DL (2024) An unmet need for pharmacology: Treatments for radiation-induced gastrointestinal mucositis. Biomed Pharmacother, 175: 116767. [ DOI:10.1016/j.biopha.2024.116767] 19. Sadrzadeh S and Tajik M (2024) Dosimetry calculations of gastric cancer treatment during pencil beam scanning proton therapy. International Journal of Radiation Research, 22(4): 823-829. [ DOI:10.61186/ijrr.22.4.823] 20. Pearlman R, Hanna R, Burmeister J, et al. (2021) Adverse effects of total body irradiation: a two-decade, single institution analysis. Adv Radiat Oncol, 6(4): 100723. [ DOI:10.1016/j.adro.2021.100723] 21. Hall JC, Hall AK, Lozko Y, et al. (2025) Safety of pelvic and abdominal radiation therapy for patients with inflammatory bowel disease: a dosimetric analysis of acute bowel toxicity. Int J Radiat Oncol Biol Phys, 121(2): 442-451. [ DOI:10.1016/j.ijrobp.2024.09.005] 22. Ko KI, Sculean A, Graves DT (2021) Diabetic wound healing in soft and hard oral tissues. Transl Res, 236: 72-86. [ DOI:10.1016/j.trsl.2021.05.001] 23. Zhao J, Zhi Z, Zhang M, et al. (2018) Predictive value of single nucleotide polymorphisms in XRCC1 for radiation-induced normal tissue toxicity. Onco Targets Ther, 11: 3901-3918. [ DOI:10.2147/OTT.S156175] 24. Maranzano E, De Angelis V, Pergolizzi S, et al. (2010) A prospective observational trial on emesis in radiotherapy: Analysis of 1020 patients recruited in 45 Italian radiation oncology centres. Radiotherapy and Oncology, 94(1): 36-41. [ DOI:10.1016/j.radonc.2009.11.001] 25. Minami M, Endo T, Hirafuji M, et al. (2003) Pharmacological aspects of anticancer drug-induced emesis with emphasis on serotonin release and vagal nerve activity. Pharmacol Ther, 99(2): 149165. [ DOI:10.1016/S0163-7258(03)00057-3] 26. Kamboj AK, Hoversten P, Leggett CL (2019) Upper gastrointestinal bleeding: etiologies and management. Mayo Clin Proc, 94(4): 697-703. [ DOI:10.1016/j.mayocp.2019.01.022] 27. Dandoy CE, Kim S, Chen M, et al. (2020) Incidence, risk factors, and outcomes of patients who develop mucosal barrier injury-laboratory confirmed bloodstream infections in the first 100 days after allogeneic hematopoietic stem cell transplant. JAMA Netw Open, 3(1): e1918668. [ DOI:10.1001/jamanetworkopen.2019.18668] 28. Villa A, Vollemans M, De Moraes A, et al. (2021) Concordance of the WHO, RTOG, and CTCAE v4.0 grading scales for the evaluation of oral mucositis associated with chemoradiation therapy for the treatment of oral and oropharyngeal cancers. Support Care Cancer, 29(10): 6061-6068. [ DOI:10.1007/s00520-021-06177-x] 29. Onal C, Kotek A, Unal B, et al. (2011) Plasma citrulline levels predict intestinal toxicity in patients treated with pelvic radiotherapy. Acta Oncol (Madr), 50(8): 1167-1174. [ DOI:10.3109/0284186X.2011.584557] 30. Ayling RM and Kok K (2018) Fecal Calprotectin. Adv Clin Chem, 87: 161-190. [ DOI:10.1016/bs.acc.2018.07.005] 31. Pouillon L, Laurent V, Pouillon M, et al. (2018) Diffusion-weighted MRI in inflammatory bowel disease. Lancet Gastroenterol Hepatol, 3(6): 433-443. [ DOI:10.1016/S2468-1253(18)30054-2] 32. Lee CL, Blum JM, Kirsch DG (2013) Role of p53 in regulating tissue response to radiation by mechanisms independent of apoptosis. Transl Cancer Res, 2(5): 412-421. 33. Yamaga S, Aziz M, Murao A, et al. (2024) DAMPs and radiation injury. Front Immunol, 15: 1353990. [ DOI:10.3389/fimmu.2024.1353990] 34. Sushma PS, UdayKumar P, Sheik A (2017) AP-1: Its Role in Gastrointestinal Malignancies. In: Nagaraju, et al. (Eds.), Role of Transcription Factors in Gastrointestinal Malignancies, Bahasa Inggeris, pp: 19-32. [ DOI:10.1007/978-981-10-6728-0_3] 35. Al-Sadi R, Guo S, Ye D, et al. (2016) TNF-α Modulation of Intestinal Tight Junction Permeability Is Mediated by NIK/IKK-α Axis Activation of the Canonical NF-κB Pathway. Am J Pathol, 186(5): 1151-1165. [ DOI:10.1016/j.ajpath.2015.12.016] 36. Mozdarani H, Mozdarani S, Pakniyat F, et al. (2025) Cytogenetic and cytotoxic effects of melatonin and saffron on lymphocytes of luminal A and luminal B breast cancer patients irradiated in vitro. International Journal of Radiation Research, 23(1): 37-43. [ DOI:10.61186/ijrr.23.1.37] 37. Wang A, Shi Z, Wang L, et al. (2023) The injuries of spleen and intestinal immune system induced by 2-Gy 60Co γ-ray whole-body irradiation. Int J Radiat Biol, 99(3): 406-418. [ DOI:10.1080/09553002.2022.2094017] 38. Li Y, Zhang Y, Wei K, et al. (2021) Review: Effect of gut microbiota and its metabolite scfas on radiation-induced intestinal injury. Front Cell Infect Microbiol, 11: 577236. [ DOI:10.3389/fcimb.2021.577236] 39. Markov AG, Livanova AA, Fedorova AA, et al. (2024) chronic ouabain targets pore-forming claudin-2 and ameliorates radiation-induced damage to the rat intestinal tissue barrier. Int J Mol Sci, 25(1): 288. [ DOI:10.3390/ijms25010278] 40. Alhasson F, Das S, Seth R, et al. (2017) Altered gut microbiome in a mouse model of Gulf War Illness causes neuroinflammation and intestinal injury via leaky gut and TLR4 activation. PLoS One, 12(3): e0172914. [ DOI:10.1371/journal.pone.0172914] 41. Velloso LA, Folli F, Saad MJ (2015) TLR4 at the crossroads of nutrients, gut microbiota, and metabolic inflammation. Endocr Rev, 36(3): 245-71. [ DOI:10.1210/er.2014-1100] 42. Kurashima Y and Kiyono H (2017) Mucosal ecological network of epithelium and immune cells for gut homeostasis and tissue healing. Annu Rev Immunol, 35: 119-147. [ DOI:10.1146/annurev-immunol-051116-052424] 43. Sheahan BJ, Freeman AN, Keeley TM, et al. (2021) Epithelial regeneration after doxorubicin arises primarily from early progeny of active intestinal stem cells. Cell Mol Gastroenterol Hepatol, 12(1): 119-140. [ DOI:10.1016/j.jcmgh.2021.01.015] 44. Cabral-Pacheco GA, Garza-Veloz I, D La Rosa CC, et al. (2020) The roles of matrix metalloproteinases and their inhibitors in human diseases. Int J Mol Sci, 21(24): 1-53. [ DOI:10.3390/ijms21249739] 45. Ido A, Numata M, Kodama M, et al. (2005) Mucosal repair and growth factors: recombinant human hepatocyte growth factor as an innovative therapy for inflammatory bowel disease. J Gastroenterol, 40(10): 925-931. [ DOI:10.1007/s00535-005-1705-x] 46. Maria OM, Eliopoulos N, Muanza T (2017) Radiation-induced oral mucositis. Front Oncol, 7: 89. [ DOI:10.3389/fonc.2017.00089] 47. Wang M, Shi J, Yu C, et al. (2023) Emerging strategy towards mucosal healing in inflammatory bowel disease: what the future holds? Front Immunol, 14: 1298186. [ DOI:10.3389/fimmu.2023.1298186] 48. Santini V (2001) Amifostine: chemotherapeutic and radiotherapeutic protective effects. Expert Opin Pharmacother, 2(3): 479-489. [ DOI:10.1517/14656566.2.3.479] 49. Kouvaris JR, Kouloulias VE, Vlahos LJ (2007) Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist, 12(6): 738-47. [ DOI:10.1634/theoncologist.12-6-738] 50. Atahan L, Özyar E, Sahin S, et al. (2000) Two cases of Stevens-Johnson syndrome: toxic epidermal necrolysis possibly induced by amifostine during radiotherapy. British Journal of Dermatology, 143(5): 1072-1073. [ DOI:10.1046/j.1365-2133.2000.03847.x] 51. Takahara M, Takaki A, Hiraoka S, et al. (2022) Metformin ameliorates chronic colitis in a mouse model by regulating interferon‐γ‐producing lamina propria CD4+ T cells through AMPK activation. The FASEB Journal, 36(2): e22139. [ DOI:10.1096/fj.202100831RR] 52. Hayakawa T, Kawasaki S, Hirayama Y, et al. (2019) A thin layer of sucrose octasulfate protects the oesophageal mucosal epithelium in reflux oesophagitis. Sci Rep, 9(1): 3559. [ DOI:10.1038/s41598-019-39087-4] 53. Coppini M, Caponio VCA, Mauceri R, et al. (2024) Efficacy of topical agents in oral mucositis prevention: Systematic review and network meta-analysis. Oral Dis, 30(7): 4126-4144. [ DOI:10.1111/odi.15046] 54. Henriksson R, Franzén L, Littbrand B (1992) Effects of sucralfate on acute and late bowel discomfort following radiotherapy of pelvic cancer. J Clin Oncol, 10(6): 969-75. [ DOI:10.1200/JCO.1992.10.6.969] 55. Dağlı Ü and Kalkan İH (2017) Treatment of reflux disease during pregnancy and lactation. Turk J Gastroenterol, 28(Suppl 1): 53-56. [ DOI:10.5152/tjg.2017.14] 56. Rahgoshai S, Mehnati P, Aghamiri MR, et al. (2021) Evaluating the radioprotective effect of Cimetidine, IMOD, and hybrid radioprotectors agents: An in-vitro study. Applied Radiation and Isotopes, 174: 109760. [ DOI:10.1016/j.apradiso.2021.109760] 57. Razzaghdoust A, Mozdarani H, Mofid B (2014) Famotidine as a radioprotector for rectal mucosa in prostate cancer patients treated with radiotherapy. Phase I/II randomized placebo-controlled trial. Strahlentherapie und Onkologie, 190(8): 739-744. [ DOI:10.1007/s00066-014-0602-8] 58. Brubaker PL (2018) Glucagon-like peptide-2 and the regulation of intestinal growth and function. Compr Physiol, 8(3): 1185-1210. [ DOI:10.1002/cphy.c170055] 59. Booth C, Booth D, Williamson S, et al. (2004) Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage. Cell Prolif, 37(6): 385-400. [ DOI:10.1111/j.1365-2184.2004.00320.x] 60. Burness CB and McCormack PL (2013) Teduglutide: a review of its use in the treatment of patients with short bowel syndrome. Drugs, 73(9): 935-947. [ DOI:10.1007/s40265-013-0070-y] 61. Wang X, Chen H, Han S, et al. (2024) The real-world analysis of adverse events with teduglutide: a pharmacovigilance study based on the FAERS database. Front Pharmacol, 15:1404658. [ DOI:10.3389/fphar.2024.1404658] 62. Peterson DE, Bensadoun RJ, Roila F (2010) Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. Annals of Oncology, 21: Suppl 5: v261-v265. [ DOI:10.1093/annonc/mdq197] 63. Benson AB, Ajani JA, Catalano RB, et al. (2004) Recommended guidelines for the treatment of cancer treatment-induced diarrhoea. Journal of Clinical Oncology, 22(14): 2918-2926. [ DOI:10.1200/JCO.2004.04.132] 64. Martenson JA, Halyard MY, Sloan JA, et al. (2008) Phase III, double-blind study of depot octreotide versus placebo in the prevention of acute diarrhea in patients receiving pelvic radiation therapy: Results of North Central Cancer Treatment Group N00CA. Journal of Clinical Oncology, 26(32): 5248-5253. [ DOI:10.1200/JCO.2008.17.1546] 65. Cantorna MT, Munsick C, Bemiss C, et al. (2000) 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr, 130(11): 2648-2652. [ DOI:10.1093/jn/130.11.2648] 66. Choi HS, Lim JY, Chun HJ, et al. (2013) The effect of polaprezinc on gastric mucosal protection in rats with ethanol-induced gastric mucosal damage: Comparison study with rebamipide. Life Sci, 93(2-3): 69-77. [ DOI:10.1016/j.lfs.2013.05.019] 67. Mahmood A, FitzGerald AJ, Marchbank T, et al. (2007) Zinc carnosine, a health food supplement that stabilises small bowel integrity and stimulates gut repair processes. Gut, 56(168-175): 168-175. [ DOI:10.1136/gut.2006.099929] 68. Johnke RM, Sattler JA, Allison RR (2014) Radioprotective agents for radiation therapy: future trends. Future Oncology, 10(2): 2345-2357. [ DOI:10.2217/fon.14.175] 69. Weigelt C, Haas R, Kobbe G (2011) Pharmacokinetic evaluation of palifermin for mucosal protection from chemotherapy and radiation. Expert Opin Drug Metab Toxicol, 7(4): 505-515. [ DOI:10.1517/17425255.2011.566556] 70. Touchefeu Y, Montassier E, Nieman K, et al. (2014) Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis - current evidence and potential clinical applications. Aliment Pharmacol Ther, 40(5): 409-421. [ DOI:10.1111/apt.12878] 71. Cereda E, Caraccia M, Caccialanza R (2018) Probiotics and mucositis. Curr Opin Clin Nutr Metab Care, 21(5): 399-404. [ DOI:10.1097/MCO.0000000000000487] 72. Lawrence YR, Paulus R, Langer C, et al. (2013) The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801. Lung Cancer, 80(3): 298-305. [ DOI:10.1016/j.lungcan.2013.02.008] 73. Anderson CM, Lee CM, Saunders DP, et al. (2019) Phase IIb, randomized, double-blind trial of GC4419 versus placebo to reduce severe oral mucositis due to concurrent radiotherapy and cisplatin for head and neck cancer. Journal of Clinical Oncology, 37(3): 3256-3265. [ DOI:10.1200/JCO.19.01507]
Send email to the article author
|
